Drug interactions in oncology

被引:204
作者
Beijnen, JH [1 ]
Schellens, JHM [1 ]
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
关键词
D O I
10.1016/S1470-2045(04)01528-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug interactions are an ongoing concern in treatment of cancer, especially when cytotoxic drugs are being used. However, the clinical relevance of these interactions is not always investigated. Drug interactions can be pharmaceutical, pharmacokinetic, or pharmacodynamic. They can also be wanted (eg, use of ciclosporin to enhance the oral bioavailability of paclitaxel); unwanted (eg, combination of the antiviral agent sorivudine and oral fluorouracil analogues can lead to fatal complications); between cytotoxic drugs, cytotoxic drugs and non-cytotoxic drugs; or with pharmaceutical vehicles. Potential interactions between anticancer drugs and over-the-counter or alternative medicines and herbs should not be underestimated. More attention should be given to the recognition of potential drug interactions in the preclinical and early clinical development phase of a new anticancer drug. Here, we provide a comprehensive overview of drug interactions, with selected examples.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 78 条
[1]  
Advani R, 2001, CLIN CANCER RES, V7, P1221
[2]   PHARMACOKINETIC DRUG-INTERACTIONS OF COMMONLY USED ANTICANCER DRUGS [J].
BALIS, FM .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :223-235
[3]   Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis [J].
Bannwarth, B ;
Pehourcq, F ;
Schaeverbeke, T ;
Dehais, J .
CLINICAL PHARMACOKINETICS, 1996, 30 (03) :194-210
[4]  
Bardelmeijer HA, 2000, CLIN CANCER RES, V6, P4416
[5]  
Bardelmeijer HA, 2002, CANCER RES, V62, P6158
[6]   The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery [J].
Bardelmeijer, HA ;
van Tellingen, O ;
Schellens, JHM ;
Beijnen, JH .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) :231-241
[7]  
BEIJNEN JH, 1994, CANCER CHEMOTH PHARM, V33, P523, DOI 10.1007/BF00686512
[8]   MITOMYCIN ANTITUMOR AGENTS - A REVIEW OF THEIR PHYSICOCHEMICAL AND ANALYTICAL PROPERTIES AND STABILITY [J].
BEIJNEN, JH ;
LINGEMAN, H ;
VANMUNSTER, HA ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1986, 4 (03) :275-295
[9]   Drug interactions in palliative care [J].
Bernard, SA ;
Bruera, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1780-1799
[10]  
Block Keith I, 2002, Integr Cancer Ther, V1, P83, DOI 10.1177/153473540200100118